Imexpharm Income Statement

Financials in millions VND. Fiscal year is January - December.

Millions VND. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Jan '25 Jan 1, 2025	Jan '24 Jan 1, 2024	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	2,393,233	2,441,085	2,205,120	1,994,037	1,643,707	1,266,597
Revenue Growth (YoY)	3.69%	10.70%	10.59%	21.31%	29.77%	-7.51%
Cost of Revenue	1,250,405	1,282,008	1,181,634	1,010,064	824,152	669,657
Gross Profit	1,142,828	1,159,077	1,023,486	983,973	819,555	596,940
Selling, General & Admin	676,503	696,642	608,328	602,926	523,055	362,868
Operating Expenses	676,503	696,642	608,328	602,926	523,055	362,868
Operating Income	466,326	462,435	415,158	381,047	296,500	234,072
Interest Expense	-16,772	-16,501	-3,489	-6,036	-3,795	-5,496
Interest & Investment Income	21,328	19,790	7,929	19,877	19,853	12,364
Currency Exchange Gain (Loss)	1,587	1,698	2,410	2,613	-2,053	3,436
Other Non Operating Income (Expenses)	-18,924	-21,175	-19,654	-20,221	-19,448	-9,413
EBT Excluding Unusual Items	453,546	446,248	402,354	377,279	291,059	234,963
Gain (Loss) on Sale of Investments	-	-	1,839	-6.02	345.28	3,896
Gain (Loss) on Sale of Assets	205.34	-	-	-	-	-
Pretax Income	453,751	446,248	404,193	377,273	291,404	238,859
Income Tax Expense	97,055	97,110	83,331	77,717	67,864	49,764
Net Income	356,695	349,138	320,862	299,556	223,540	189,095
Preferred Dividends & Other Adjustments	45,573	44,749	45,000	21,778	39,697	15,582
Net Income to Common	311,122	304,389	275,862	277,778	183,844	173,513
Net Income Growth	6.99%	8.81%	7.11%	34.01%	18.22%	-9.83%
Shares Outstanding (Basic)	154	154	154	154	154	154
Shares Outstanding (Diluted)	154	154	154	154	154	154
Shares Change (YoY)	-3.92%	-	-	-0.00%	-0.00%	2.92%
EPS (Basic)	2020.16	1976.44	1791.21	1803.65	1193.71	1126.63
EPS (Diluted)	2020.16	1976.44	1791.21	1803.65	1193.64	1126.63
EPS Growth	8.60%	10.34%	-0.69%	51.11%	5.95%	-6.15%
Free Cash Flow	277,856	27,292	119,497	-103,064	279,250	182,024
Free Cash Flow Per Share	1804.15	177.21	775.91	-669.21	1813.19	1181.89
Dividend Per Share	-	-	500.000	454.546	432.901	649.351
Dividend Growth	-	-	10.00%	5.00%	-33.33%	-
Gross Margin	47.75%	47.48%	46.41%	49.35%	49.86%	47.13%
Operating Margin	19.48%	18.94%	18.83%	19.11%	18.04%	18.48%
Profit Margin	13.00%	12.47%	12.51%	13.93%	11.19%	13.70%
Free Cash Flow Margin	11.61%	1.12%	5.42%	-5.17%	16.99%	14.37%
EBITDA	568,434	565,411	520,794	463,689	356,886	294,484
EBITDA Margin	23.75%	23.16%	23.62%	23.25%	21.71%	23.25%
D&A For EBITDA	102,109	102,976	105,636	82,642	60,386	60,412
EBIT	466,326	462,435	415,158	381,047	296,500	234,072
EBIT Margin	19.48%	18.94%	18.83%	19.11%	18.04%	18.48%
Effective Tax Rate	21.39%	21.76%	20.62%	20.60%	23.29%	20.83%
Revenue as Reported	2,393,233	2,441,085	2,205,120	1,994,037	1,643,707	1,266,597
Advertising Expenses	-	161,446	170,332	175,099	123,665	110,468

Source: S&P Global Market Intelligence. Standard template. Financial Sources.